886230-76-8Relevant articles and documents
Axitinib intermediate synthesis method
-
, (2019/07/04)
The invention relates to an axitinib intermediate synthesis method, and belongs to the field of chemical synthesis, wherein a target compound is obtained through a Vilsmeier reaction, pyranyl protection, a wittig reaction, a reduction reaction and an iodo reaction. According to the present invention, the palladium catalytic reaction is replaced with the wittig reaction, such that the use of the expensive palladium catalyst can be avoided, the post-treatment can be conveniently performed, and the production cost is saved.
2,3-dimethyl-6-urea -2H-indazoles and its preparation method and application
-
, (2016/10/09)
The invention discloses a 2, 3-dimethyl-6-urea-2H-indazole compound shown by the following general formula (I), medicinal salt or a solvent compound thereof, wherein Ar is substituted or unsubstituted phenyl or aromatic matrix. The invention also discloses a preparation method and application of the compound. The compound can regulate signal transduction of tyrosine kinase, inhibit bad cellular proliferation, and particularly has obvious curative effect for tumors.
Effective Laboratory-Scale Preparation of Axitinib by Two CuI-Catalyzed Coupling Reactions
Zhai, Li-Hai,Guo, Li-Hong,Luo, Yang-Hui,Ling, Yang,Sun, Bai-Wang
, p. 849 - 857 (2015/07/27)
The discovery and development of an efficient synthesis route to axinitib is reported. The first-generation route researched by Pfizer implemented two Pd-catalyzed coupling reactions as key steps. In this work, the development of Heck-type and C-S coupling reactions catalyzed by CuI is briefly described, using an economial and practical protocol. Aspects of this route, such as selecting optimal ligands, solvent, and other conditions, are discussed in detail. The scale-up experiment was carried out to provide more than 300 g of active pharmaceutical ingredients of axitinib in Form XLI with 99.9% purity in 39% yield. In short, we provide a new choice of synthesis route to axitinib, through two copper-catalyzed coupling reactions with good yield.